E-therapeutics Plc
ETXPF · OTC
1/31/2025 | 7/31/2024 | 1/31/2024 | 7/31/2023 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -1% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -67.1% | -69.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -3,900.6% | -3,972.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -3,526.6% | -3,496.2% |
| EPS Diluted | -0.011 | -0.011 | -0.01 | -0.01 |
| % Growth | 2.6% | -19.4% | 0.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |